What is Noble Financial’s Estimate for ELDN Q2 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities research analysts at Noble Financial issued their Q2 2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.22) for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.86) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.20.

Separately, Guggenheim started coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a “buy” rating and a $9.00 price target for the company.

Eledon Pharmaceuticals Stock Up 0.7%

ELDN stock opened at $3.06 on Wednesday. The company has a market capitalization of $183.24 million, a PE ratio of -1.52 and a beta of 0.08. The stock’s 50 day moving average is $3.15 and its two-hundred day moving average is $3.92. Eledon Pharmaceuticals has a 52-week low of $2.30 and a 52-week high of $5.54.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ELDN. RA Capital Management L.P. bought a new position in shares of Eledon Pharmaceuticals during the fourth quarter worth about $14,693,000. Sphera Funds Management LTD. raised its stake in Eledon Pharmaceuticals by 96.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company’s stock valued at $10,513,000 after buying an additional 1,254,298 shares in the last quarter. First Light Asset Management LLC bought a new position in Eledon Pharmaceuticals during the 4th quarter worth approximately $9,595,000. Blue Owl Capital Holdings LP acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter worth approximately $8,075,000. Finally, Woodline Partners LP grew its position in shares of Eledon Pharmaceuticals by 98.3% in the 4th quarter. Woodline Partners LP now owns 1,671,822 shares of the company’s stock worth $6,888,000 after acquiring an additional 828,930 shares in the last quarter. Institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).